Search PubMed⌕ Search

Biomedical subjects

M Dallocchio

Publications and source records attributed to M Dallocchio.

197 records · Page 11Linked to original sources
PubMedDate not supplied

[Rilmenidine, a new antihypertensive agent in the first line treatment of essential arterial hypertension. Multicenter double-blind study versus atenolol].

After 4 weeks on placebo, 90 hypertensive patients (37 men, 53 women, mean age 55 years) with systolic (SBP) and diastolic (DBP) blood pressures of 162/99 and 165/100 mmHg respectively received double-blind treatment with either rilmenidine 1 mg/day or atenolol 50 mg/day. This treatment was given alone for 8 weeks, with possible DBP greater than or equal to 90 mmHg, hydrochlorothiazide 25 mg/day was added between the 9th and 12th weeks of treatment. At week 13 all treatments were replaced by placebo. Both groups were similar at randomisation, and both treatments were similarly effective: after 8 weeks of monotherapy with rilmenidine or atenolol, the SBP/DBP had decreased by -18/-13 mmHg and by -21/-15 mmHg respectively, and the proportion of patients with normalised blood pressure (SBP/DBP less than or equal to 160/90 mmHg) was 66 percent and 65 percent. Effectiveness was maintained at 12 weeks, when less than 20 percent of the patients had taken hydrochlorothiazide. Both drugs were well tolerated clinically and electrocardiographically. There was a significantly greater decrease in heart rate on atenolol than on rilmenidine. Eleven patients (5 on rilmenidine, 6 on atenolol) dropped out of the trial, 2 and 3 patients in the respective groups on account of side-effects. Laboratory tests showed that the HDL-cholesterol level significantly decreased on atenolol and remained stable on rilmenidine (P less than 0.01), whereas the LDL-cholesterol level was stable on atenolol and decreased on rilmenidine (P less than 0.05). No rebound in blood pressure was observed on discontinuation of both treatments. This study shows that rilmenidine administered as first-line treatment is as effective as atenolol in lowering blood pressure, and it confirms that this drug is clinically and biochemically well tolerated.

Adult↗
PubMedDate not supplied

Ambulatory blood pressure monitoring. Values in normotensive patients and suggestions for interpretation.

We performed 24 hours ambulatory blood pressure monitoring with non invasive devices in 233 normotensive patients during a workday. Their age ranged from 21 to 74 years (mean +/- standard deviation = 39 +/- 11, 37% females). These patients were mainly recruited on their workplace. Blood pressure monitoring was proposed to all volunteers without any history of hypertension, independently of the casual blood pressure measured by a doctor after 10 minutes sitting, just before monitoring. Patients were asked to note precisely their bedtime and the moment of getting up and to start a blood pressure measurement as getting up. This measure was used as the starting point of the 24 hours blood pressure curve for each patient. Pooling all patients in that way shows an important rise of blood pressure as standing up but no significant variation before. So we calculated the average blood pressure during the true time of activity and of bedrest for each block of 10 years from 20 to 60 years, separately for men and women. These values may be used as a guide when interpreting 24 hours blood pressure recordings.

Adult↗
PubMedDate not supplied

[Calcium inhibitors and cardioprotection].

The main goal in treating hypertensive patients is to reduce the incidence of complications, especially on the heart. The lowering of blood pressure do not seem enough. Some properties, not shared by all antihypertensive drugs, are likely to allow some protection against heart and coronary diseases. These properties are: the absence of deleterious effects on glucids, lipids and kaliemia; the ability to induce left ventricular hypertrophy regression, antiarrhythmics effects, anti-ischemic effects and the ability to improve arterial compliance. Calcium inhibitors share all these properties and also have some more original and beneficial effects on arterial spasm and may be on progression of atherosclerosis. For all these reasons, a great interest arise for this new therapeutic class in hypertension. However we are still waiting for the demonstration of a true cardiac protection in hypertension with controlled long term trials.

Animals↗
PubMedDate not supplied

[The coronary hypertensive: therapeutic principles].

Since arterial hypertension is one the main risk factors of coronary atherosclerosis, the association hypertension-coronary disease is a frequent one. Moreover, arterial hypertension aggravates the coronary disease and this association is therefore of very poor prognosis. However, this prognosis seems to improve with early and adapted treatment based largely at this time on beta-blockers and calcium inhibitors.

Adrenergic beta-Antagonists↗
PubMedDate not supplied

[Phechromocytoma].

Explore the source record for details and available documents.

Arrhythmias, Cardiac↗
PubMedDate not supplied

[Cutaneous manifestation of pheochromocytoma. Report of a case (author's transl)].

A 33 years old woman was investigated for paroxystic hypertension worsened by bêta-adrenergic blocking drugs therapy. Clinical investigation revealed cutaneous abnormalities with erythemato-macular eruption on dorsalis faces of both hands. These lesions were histologically non specific with capillaritis and oedema. angiography revealed a left sided pheochromocytoma. Cutaneous abnormalities disappear after intervention. Pheochromocytoma is rarely associated with cutaneous disease: most papers describe intermittent "flush" phenomenon. Permanent lesions are non fréquent: erythrocyanosis, rash with nodosities or macular lesions, restricted places of necorsis, distal necorsis, hypochromic lesions. The variability of cutaneous disease of pheochromocytoma seems reliable to the biochemical structure of catecholamine secreted by tumor.

Adrenal Gland Neoplasms↗